A randomised, double-blind, parallel-group, placebo controlled study of esomeprazole i.v. (bolus infusion of 80 mg followed by a continuous infusion of 8 mg per hour) administered for 72 hours to assess prevention of rebleeding in subjects that have undergone successful primary endoscopic haemostasis of a bleeding peptic ulcer – the PUB study.
18 Years +
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
No locations available